Press Room

News / Jun 02, 2021

Have your say and cast your vote for Guy Villax

EY World Entrepreneur Of The Year™ 2021 is the world's most prestigious business award for entrepreneurs

Guy Villax - EY World Entrepreneur Of The Year™ 2021 | Hovione

We are in countdown to the election of EY World Entrepreneur Of The Year™ 2021, the world's most prestigious business award for entrepreneurs and Guy Villax, CEO of Hovione, is a candidate. 

Vote and support Guy Villax, as no Portuguese has ever won this global award.

Guy Villax, CEO of Hovione, won the Portuguese election and is one of 38 candidates who, on June 10 – a special day in Portugal as we celebrate the Day of Portugal across all the Portuguese communities around the globe – can be chosen by the jury and supported by anyone who wants to participate in the open voting.

Vote and support Hovione. Support Guy Villax.

Saving lives is the driving force behind family pharma business Hovione.

 

Cast your vote here

 

Learn more about this award

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026